

Development and validation of Eco friendly second order derivative UV-Vis spectrophotometric method for the estimation of Vonoprazan and Aspirin in synthetic mixture
Abstract
Aspirin is used for its analgesic, antipyretic and anti-inflammatory properties having adverse effect on stomach like ulceration and bleeding on stomach lining. As a consequence, Vonoprazan fumarate which is an acid protective agent for gastrointestinal tract is used along with Aspirin. Present study reports eco-friendly Second order derivative UV spectroscopic method for simultaneous estimation of Aspirin and Vonoprazan in combination. Distilled water was used as solvent. The zero crossing point (ZCP) was observed at 229.4 nm and 221.0 nm for Vonoprazan and Aspirin, respectively. The method was found to be linear with a concentration range of 4-20 µg/ml for Vonoprazan and 15-50 µg/ml for Aspirin, respectively. The method was validated as per ICH guideline Q2 (R2) guideline. The recovery studies confirmed the accuracy of the methods. Relative standard deviations for repeatability, inter-day and intra-day assays were less than 2%. The described derivative spectrophotometric methods are found to be specific, accurate, precise, and robust. The method was successfully applied for the estimation of synthetic mixture of Aspirin and Vonoprazan. The developed method is evaluated in AGREE GREENNESS software and found to be eco-friendly.
References
Indian pharmacopeia; 9th Edn, Indian Pharmacopeia Commission, New Delhi, 2022, volume II, 1515p.
National Center for Biotechnology Information (2024). PubChem Compound Summary for CID 2244, Aspirin. Accessed on January 28, 2024 https://pubchem.ncbi.nlm.nih.gov/compound/Aspirin.
Shin, J.M., Inatomi, N., Munson, K., et al. “Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase,1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine mono-fumarate (TAK-438)”. National Library of Medicine. 2011, 339(2), 412-420p .
National Center for Biotechnology Information (2024). PubChem Compound Summary for CID 15981397, Vonoprazan. Accessed on January 28, 2024 https://pubchem.ncbi.nlm.nih.gov/compound/Vonoprazan.
Launch of Aspirin/Vonoprazan Fumarate Combination Tablets: "Cabpirin® Combination Tablets"accessed on January 28 2024, https://www.otsuka.co.jp/en/company/newsreleases/2020/20200522_1.html#:~:text=The%20Cabpirin%20combination%20tablet%20contains,it%20could%20improve%20patient%20adherence.
Sakurai, Yuuichi & Shiino, Madoka & Horii, Sayako & Okamoto, Hiroyuki & Nakamura, Koki & Nishimura, Akira & Sakata, Yukikuni. (2016). Pharmacokinetic Drug-Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men. Clinical drug investigation.2017, 37(1), 39-49p.
Indian pharmacopeia; 9th Edn, Indian Pharmacopeia Commission, New Delhi, 2022, volume II, 1515p.
British pharmacopeia ,British Pharmacopeia Commission, Great Britain, 2011,volume I , 188p.
British pharmacopeia, British Pharmacopeia Commission, Great Britain ,2011,volume III, 2442p.
United State Pharmacopeia National Formulary, monograph of aspirin, 2017, 1-2p.
Refbacks
- There are currently no refbacks.